Giuseppe
Emeritus
Complications: tracking down the data on oseltamivir -- Cohen 339: b5387 (BMJ, extract, edited)
Published 8 December 2009, doi:10.1136/bmj.b5387
Cite this as: BMJ 2009;339:b5387
Feature
Complications: tracking down the data on oseltamivir
Deborah Cohen, BMJ
dcohen@bmj.com
Editorial, doi:10.1136/bmj.b5351
Research, doi:10.1136/bmj.b5106
Analysis, doi:10.1136/bmj.b5164
Analysis, doi:10.1136/bmj.b5248
Letter, doi:10.1136/bmj.b5364
A Cochrane group?s attempt to reproduce an analysis underpinning the use of oseltamivir in pandemic influenza hit a brick wall. Deborah Cohen retraces its steps
The first 150 words of the full text of this article appear below.
It started this July with an inquiry from a Japanese paediatrician, Keiji Hayashi, to the Cochrane Collaboration about its 2008 review of the treatment of influenza with oseltamivir.
"You described that oseltamivir 150 mg daily prevented lower respiratory tract complications," commented Dr Hayashi. "However, we have found that this conclusion is based on the other review by Kaiser and colleagues1 and not on your own data analysis."
Hayashi suspected that Kaiser?s conclusion about complications was mainly determined by data from eight unpublished randomised controlled trials (box 1).
(...)
-
<cite cite="http://www.bmj.com/cgi/content/extract/339/dec08_3/b5387">Complications: tracking down the data on oseltamivir -- Cohen 339: b5387 -- BMJ</cite>Cite this as: BMJ 2009;339:b5387
Feature
Complications: tracking down the data on oseltamivir
Deborah Cohen, BMJ
dcohen@bmj.com
Editorial, doi:10.1136/bmj.b5351
Research, doi:10.1136/bmj.b5106
Analysis, doi:10.1136/bmj.b5164
Analysis, doi:10.1136/bmj.b5248
Letter, doi:10.1136/bmj.b5364
A Cochrane group?s attempt to reproduce an analysis underpinning the use of oseltamivir in pandemic influenza hit a brick wall. Deborah Cohen retraces its steps
The first 150 words of the full text of this article appear below.
It started this July with an inquiry from a Japanese paediatrician, Keiji Hayashi, to the Cochrane Collaboration about its 2008 review of the treatment of influenza with oseltamivir.
"You described that oseltamivir 150 mg daily prevented lower respiratory tract complications," commented Dr Hayashi. "However, we have found that this conclusion is based on the other review by Kaiser and colleagues1 and not on your own data analysis."
Hayashi suspected that Kaiser?s conclusion about complications was mainly determined by data from eight unpublished randomised controlled trials (box 1).
(...)
-